INCHEON, Korea I June 12, 2025 I Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) today presented the long-term safety data of EPYSQLI™ (eculizumab; SB12), a ...

Samsung Bioepis Co., Ltd. ("Samsung Bioepis") today presented the long-term safety data of EPYSQLItm (eculizumab; SB12), a biosimilar to Soliris1, in paroxysmal nocturnal hemoglobinuria (PNH) at the ...

mechanism of action, and critical attributes like C5 inhibition. Clinical studies in patients with PNH confirmed comparable efficacy, safety, and pharmacokinetics between the biosimilars and reference ...

Understanding a drug’s mechanism of action (MOA) can greatly increase the likelihood of successful clinical trials by identifying biomarkers of patient response and providing a rationale for ...

In a review published in the Journal of Dermatologic Science and Cosmetic Technology, two Chinese researchers looked into the mechanism of action of preservatives in cosmetics. Co-author Zhenyu ...

Eculizumab effectively reduced MG-ADL scores ... Myasthenia gravis: molecular mechanisms and promising therapeutic strategies. Biochem Pharmacol. 2023;218:115872. doi:10.1016/j.bcp.

Eculizumab therapy showed no clear difference from ravulizumab ... Their half-lives, expected mechanisms of action and these observations indicate that their treatment effect is transient and that ...

The recommended dose of Soliris in adults with PNH is 600 mg every week for 4 weeks, followed by 900 mg in week 5 and then 900 mg every 2 weeks after the fifth dose. 3 Soliris is supplied in 30 mL ...

“We are encouraged by the results of this AD trial exploring how targeting the disease from different angles with different mechanisms of action impacts disease markers,” said Kreesten ...